An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Cushing's Syndrome
Interventions
DRUG

mifepristone

Mifepristone 300 mg to 1200 mg once daily

Trial Locations (15)

21215

Sinai Hospital of Baltimore, Baltimore

33021

The Center for Diabetes and Endocrine Care, Hollywood

35294

University of Alabama at Birmingham School of Medicine, Birmingham

39216

University of Mississippi Medical Center, Jackson

44195

Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism, Cleveland

48109

University of Michigan Medical Center, Ann Arbor

53051

Endocrinology Center at Community Medical Commons, Menomonee Falls

60611

Northwestern University Feinberg Medical; Division of Endocrinology, Metabolism & Molecular Medicine, Chicago

73104

Oklahoma Diabetes Center, Oklahoma City

87131

University of New Mexico, Albuquerque

92026

AMCR Institute Inc., Escondido

97239

Oregon Health Sciences University, Portland

94305-5826

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

75390-8857

University of Texas Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY